Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Early real-world treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with eribulin after prior immuno-oncology or antibody–drug conjugate therapy. Clin Breast Cancer. 2023 Nov 16;15:855-65. doi: 10.2147/BCTT.S422025
Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Jeuland M, McClatchey M, Patil SR, Pattanayak SK, Poulos CM, Chen Yang J. Do decentralized community treatment plants provide clean water? Evidence from rural Andhra Pradesh, India. Land Econ. 2021 May;97(2).
Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, Stearn V. Treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR-/HER2– advanced breast cancer enrolled in an expanded access program. Clin Breast Cancer. 2019 Oct;19(5):317-25. doi: 10.1016/j.clbc.2019.04.005
Liu X, Sarr M, Swanson T. Resistance to the regulation of common water resources in rural Tunisia. Land Econ. 2015 Aug;91:435-59. doi: 10.3368/le.91.3.435
Mansfield CA, Phaneuf D, Johnson FR, Yang J, Beach RH. Preferences for public lands management under competing uses: the case of Yellowstone National Park. Land Econ. 2008 May 1;84(2):282-305.
Mansfield CA, Van Houtven GL, Huber J. Compensating for public harms: why public goods are preferred to money. Land Econ. 2002;78(3):368-89.